Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials

Shattuck Labs, Inc.

Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.
OrbiMed led round; participation from Adage Capital, Redmile Group, Coastlands Capital, Prosight Capital, NextBio Capital.
Proceeds to fund SL-325 Phase 1 (start Q3 2025) and multiple Phase 2 trials including IBD; cash runway into 2029.
Common warrants ($1.0846 exercise) expire 30 days after public Phase 1 data announcement, expected in 2026.
Closing contingent on IND clearance for SL-325; certain investors receive board designation rights at closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.